FBRX
Forte Biosciences·NASDAQ
--
--(--)
--
--(--)
5.00 / 10
Netural
Fund flow is positive with a score of 7.62/10; Extra-large and block inflows trend positively, though small/medium/large flows are negative. This indicates institutional interest despite retail hesitation. Analyst coverage is limited to two analysts—Daniil Gataulin (Strong Buy) and Gavin Clark-Gartner (Buy)—with a historical weighted rating of 2.39. The consensus is mildly bullish, aligning with the positive fund flow and supporting a cautiously optimistic view.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-17
InstitutionChardan Capital
Times predicted4
Historical Win Rate25.0%
Is money flowing into or out of FBRX?
- FBRX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.00/10 (Netural).
